home > news > detailed info

Signant Health Appoints Lawrence Miller as Chief Technology Officer

Signant Health

Silicon Valley Innovator Expands Dynamic Leadership Team Committed to Advancing Clinical Research Technology

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.

Mike Nolte, CEO of Signant Health, said, “Adding an accomplished technology leader like Lawrence Miller to our team has an immediate impact on our innovation agenda and sets up a clear roadmap for accelerating customer success. Lawrence brings Silicon Valley substance and fluency to our business along with deep engineering expertise, and I expect him not only to be an asset to our business, but to take a pioneering role in this industry. I’m thrilled he’s joining the more than 1,500 innovative, exceptional people at Signant, and I know he will be a great partner for our customers, investors and other stakeholders.”

Added Miller, "From my perspective looking into the industry, clinical research companies have been seen as behind the technology curve not because they are inherently slow adopters, but because historically vendors have failed to provide truly dynamic, reliable and integrated solutions. Fortunately, this perception, and this reality, are beginning to change. Collectively, we have a responsibility to build solutions that not only work, but that sites, study teams and patients want to use. I am proud to bring my experience and passion for developing exceptional software to Signant Health as we partner with our sponsor and CRO customers to transform the value, usability and trust of enterprise-wide clinical research technology.”

Miller joins Signant Health from Symphony Communication Services, a cloud based secure collaboration company. As Chief Security Officer he was responsible for the integrity and security of the platform’s end-to-end encrypted messaging system, handling operational security, cloud platform operations, technology risk management and policy. He also oversaw development and engineering for the firm’s next-generation messaging architecture and advised federal financial regulators on cybersecurity issues.

Prior to joining Symphony, Miller worked for BlackRock for 11 years in both New York and San Francisco, where he was a Managing Director, overseeing the Development Services team for Aladdin, BlackRock’s asset management platform. Miller’s earlier career was with JP Morgan Chase, leading development for one of the firm’s electronic trading platforms.

Miller holds a BA in Physics from the University of Chicago and an MS in Computer Science from The George Washington University.

To learn more about Signant Health and the most comprehensive patient-technology suite for eCOA, eConsent, Patient Engagement, IRT, Clinical Supply Management, and Endpoint Quality solutions, visit


Who Is Signant Health?

The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. Take a significant step toward patient-centricity at

CRF Health and Bracket are now Signant Health.

Contact:, +1 267.498.2350
phone +1 267 498 2300
email 4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462
Print this page
Send to a friend
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

BioT ULT Transporter


The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement